Research programme: atherosclerosis and metabolic disorder therapies - AtheroNova

Drug Profile

Research programme: atherosclerosis and metabolic disorder therapies - AtheroNova

Alternative Names: AHRO-003; AHRO-010; AHRO-100; AHRO-200; AHRO-300; HDCA - AtheroNova; Hyodeoxycholic acid - AtheroNova

Latest Information Update: 07 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AtheroNova
  • Class Bile acids and salts; Terpenes
  • Mechanism of Action Cholesterol absorption inhibitors; Gene expression stimulants; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Lipid metabolism disorders; Obesity; Stroke

Most Recent Events

  • 18 Jul 2014 AtheroNova files a pre-IND application under section 505(b) with the US FDA for Lipid metabolism disorders
  • 25 Jun 2013 A lead compound (AHRO 001) from this research programme has entered clinical development
  • 30 Oct 2012 Preclinical trials in Lipid metabolism disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top